Track topics on Twitter Track topics that are important to you
CardioVascular BioTherapeutics, Inc. (OTC/BB: CVBT) is a biopharmaceutical company focused on developing protein drug candidates to be used in the treatment of cardiovascular disease, the worldwide leading cause of death. The Company is developing injectable and topical formulations of its active pharmacological ingredient (API) to facilitate the growth of new blood vessels (angiogenesis) in the heart, tissues and organs that have been compromised by impaired blood supply (hypoxia, ischemia). The Company’s API contains FGF-1141 a human protein manufactured using a proprietary technology. FGF-1 stimulates the growth and proliferation of the three main cell types of blood vessels; endothelial cells, smooth muscles cells and pericytes. CVBT-141A, the Company’s lead drug candidate successfully completed initial clinical trials in Germany during the 1990s, with no drug-related adverse events and a statistically significant increase in localized blood vessel growth (and perfusion) both in patients also receiving coronary by-pass procedures and in patients with severe coronary heat disease (CHD) receiving CVBT-141A, as the sole therapy. Enrollment and treatment has been completed in an FDA authorized Phase I study with CVBT-141A, administered via injection in severe CHD patients. The protocol design for the Phase II trial is underway, with FDA input, and is planned to initiate in 2007. CardioVascular BioTherapeutics, Inc. is committed to conducting additional clinical trials to establish the positive effect of FGF-1141 aimed at improving the quality of life for those suffering from heart disease, stroke, diabetic wounds, or peripheral artery disease, and pledges to continue exploration for additional applications of FGF-1.
1635 Village Center Circle
United States of America
Phone: (702) 248-1174
Iovance Biotherapeutics, a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, changed its corporate name from Lion Biotechnologies t...
Pfizer is building a $200m (€179m) R&D centre in Chesterfield, Missouri at which it will consolidate biotherapeutics process development operations in the region.
Iovance Biotherapeutics, a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, announced the appointment of Timothy E. Morris as Chie...
NewsPierre Fabre Pharmaceuticals acquires promising assets from Igenica Biotherapeutics in the field of immuno-oncology.
Agilis Biotherapeutics, a biotechnology company advancing innovative DNA therapeutics for rare genetic diseases that affect the central nervous system (CNS), and Gene Therapy Research Institution (GTR...
Aeglea BioTherapeutics Inc. (enzyme-based therapeutics for rare diseases and cancer) netted $11.7mm through a follow-on public offering of 3mm common shares at $4.10. The company will use the offerin...
French private pharmaceutical group Pierre Fabre has signed a new definitive purchase agreement to acquire several assets from US biotechnology company Igenica Biotherapeutics.
Tuesday, September 5th 2017 at 12:00pm UTC CAMBRIDGE, Mass.–(BUSINESS WIRE)– Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage clinical oncology company advancing a broad pipeline o...
Plasma Protein Fraction (Human) 5%, USPPlasmanate®
Albumin (Human) 5%, USPPlasbumin ®-5
Albumin (Human) 5%, USPPlasbumin ®-5
Immune Globulin (Human)GamaSTAN™ S/DSolvent/Detergent Treated
Albumin (Human) 20%, USPPlasbumin®-20
The need for novel approaches to cardiovascular drug development served as the impetus to convene an open meeting of experts from the pharmaceutical industry and academia to assess the challenges and ...
Despite Korean Americans being one of the fastest growing immigrant groups in the United States, little is known about their cardiovascular health or cardiovascular disease risk factors.
Type 2- diabetes mellitus (T2DM) represents a major risk factor for cardiovascular complications and mortality. Strict glucose control in the early course of the disease prevents cardiovascular compli...
Prisoners are disproportionately affected by cardiovascular disease and its risk factors. However, primary prevention of cardiovascular disease in correctional settings has been widely neglected, and ...
The purpose of this study is to identify risks for cardiovascular events in a follow up period of 10 years.
To determine the combined effects of job strain and social isolation on cardiovascular morbidity and mortality.
The purpose of this study is to determine if Vitamin D supplementation helps prevent recurrent cardiovascular events, such as heart attack or stroke, in patients who have already experienc...
The purpose of this study is to improve cardiovascular disease (CVD) outcomes in racial and ethnic minorities in Hawaii.
To evaluate the effects of genetic variants in all of the nine adrenergic receptor subtype genes, alone or in combination, on cardiovascular reactivity and other quantitative cardiovascula...
Axial Biotherapeutics is a biopharmaceutical company harnessing the link between the human gut microbiome and the central nervous system to develop a new class of biotherapeutics ...
CardioVascular BioTherapeutics, Inc. (OTC/BB: CVBT) is a biopharmaceutical company focused on developing protein drug candidates to be used in the treatment of cardiovascular disease, the worldwide le...
Cardiovascular Consultants, Ltd., founded in 1986 by Dr. Andrei Damian, is dedicated to providing patients in Phoenix and surrounding areas with the most advanced and appropriate ...
Cardiovascular Consultants Ltd., founded in 1986 by Dr. Andrei Damian, is dedicated to providing patients in Phoenix and surrounding areas with the most advanced and appropriate c...
NaPro BioTherapeutics, Inc. is a natural product pharmaceutical company focused primarily on the development, manufacture and commercializa tion of paclitaxel, a naturally-occurring anti-cancer agent ...
We have published hundreds of CardioVascular BioTherapeutics news stories on BioPortfolio along with dozens of CardioVascular BioTherapeutics Clinical Trials and PubMed Articles about CardioVascular BioTherapeutics for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of CardioVascular BioTherapeutics Companies in our database. You can also find out about relevant CardioVascular BioTherapeutics Drugs and Medications on this site too.
Cardiovascular disease (CVD)
Acute Coronary Syndromes (ACS) Blood Cardiovascular Dialysis Hypertension Stent Stroke Vascular Cardiovascular disease (CVD) includes all the diseases of the heart and circulation including coronary heart disease (angina...
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...